Reduced FKBPL levels, leading to enhanced angiogenesis, implicates a possible role in diseases other than cancer, such as cardiovascular and wound healing disease, thus extending the therapeutic utility of targeting FKBPL. This evidence concerns the gene FKBPL and cancer.